Literature DB >> 32251365

Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy.

Jeffrey D Jensen1, Michael Lynch2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32251365      PMCID: PMC7133120          DOI: 10.1038/s41437-020-0314-z

Source DB:  PubMed          Journal:  Heredity (Edinb)        ISSN: 0018-067X            Impact factor:   3.821


× No keyword cloud information.
With the rapid global spread of SARS-CoV-2, tremendous efforts have been focused upon potential treatment strategies (Li and De Clercq 2020). Evolutionary theory has an important role to play in this search, and we here discuss one potentially under-appreciated research avenue. Within the field of population genetics, the phenomenon of mutational meltdown—in which a population may become extinct owing to the accumulation of deleterious mutations—has been well studied both theoretically and experimentally. The key to understanding this effect is a consideration of the efficacy of natural selection. Because there are many more ways to disrupt rather than to improve genomic function, the vast majority of new fitness-impacting mutations are deleterious rather than beneficial. Thus, if mutation rates are increased, the result is a disproportionate excess of variants that are detrimental to the organism. Because natural selection will not be able to purge this input of deleterious mutations if the mutational pressure is sufficiently large, these variants may remain in the population and even reach fixation. This deleterious load further restricts the ability of natural selection to purge additional variants, allowing more deleterious mutations to accumulate and fix, and so on—a snowball effect that can result in the eventual loss of the population (i.e., mutational meltdown). Lynch and Gabriel (1990) and Lynch et al. (1993) described this model, which is dependent on the carrying capacity of the population, the absolute population growth rate, the deleterious effect of mutations, and the deleterious mutation rate. Under this model, if the input of deleterious mutations is sufficiently high, the number of reproducing individuals will decline. Though the model of lethal mutagenesis is also commonly noted in this regard (e.g., Bull et al. 2007), the mutational meltdown framework is in fact more general, and critically incorporates the stochastic effects inherent to natural populations (see Matuszewski et al. 2017). While meltdown has been discussed largely in the negative context of a threat to small or endangered populations, it also has relevance in the positive context of inducing the extinction of a viral population within a patient. One drug in particular, favipiravir, has been demonstrated to inhibit the RNA-dependent RNA polymerase (RdRp) of RNA viruses (Furuta et al. 2013; Baranovich et al. 2013), and in vitro studies in influenza A virus (IAV) have specifically examined the relevance of a mutational-meltdown model in the presence of this inhibitor. Bank et al. (2016), utilizing experimental passaging at different drug concentrations, described potential viral adaptation at low-concentrations. However, at higher concentrations, mutations accumulated at a nearly linear rate until a transition point was reached, at which a sharp increase in mutational accumulation was observed, followed by population collapse. Significantly, as opposed to targeting a specific genomic region, this input of deleterious mutations is a genome-wide effect, raining deleterious variants on all functionally essential genomic regions. Also working in IAV, Ormond et al. (2017) examined the combined effect of favipiravir with oseltamivir, a widely-used treatment with well-studied resistance mutations. A similar mutational meltdown outcome was observed, with the selective sweeps of oseltamivir-resistant mutations appearing to actually speed population decline, owing to the resulting hitchhiking of linked deleterious variants in the viral population (and see the related work of Pénnison et al. 2017). We believe that these results at least suggest the potential therapeutic value of inducing mutational meltdown in SARS-CoV-2 patient populations. While interest in favipiravir is currently motivating clinical trials, with initial results as of March 2020 suggesting faster viral clearance compared to other tested drug treatments (Dong et al. 2020), in vitro studies will also be of great value to understand the interplay of mutational meltdown dynamics with the noteworthy biological differences of CoV-2 relative to the better studied IAV (Smith et al. 2013). Thus, while many key questions remain in need of exploration, results to date demonstrate the importance of this effort, and highlight the great value of utilizing population genetic theory to address such crucial public health concerns.
  12 in total

1.  Theory of lethal mutagenesis for viruses.

Authors:  J J Bull; R Sanjuán; C O Wilke
Journal:  J Virol       Date:  2007-01-03       Impact factor: 5.103

2.  Dynamics and Fate of Beneficial Mutations Under Lineage Contamination by Linked Deleterious Mutations.

Authors:  Sophie Pénisson; Tanya Singh; Paul Sniegowski; Philip Gerrish
Journal:  Genetics       Date:  2017-01-18       Impact factor: 4.562

3.  MUTATION LOAD AND THE SURVIVAL OF SMALL POPULATIONS.

Authors:  Michael Lynch; Wilfried Gabriel
Journal:  Evolution       Date:  1990-11       Impact factor: 3.694

4.  Therapeutic options for the 2019 novel coronavirus (2019-nCoV).

Authors:  Guangdi Li; Erik De Clercq
Journal:  Nat Rev Drug Discov       Date:  2020-03       Impact factor: 84.694

5.  T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro.

Authors:  Tatiana Baranovich; Sook-San Wong; Jianling Armstrong; Henju Marjuki; Richard J Webby; Robert G Webster; Elena A Govorkova
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

6.  An experimental evaluation of drug-induced mutational meltdown as an antiviral treatment strategy.

Authors:  Claudia Bank; Nicholas Renzette; Ping Liu; Sebastian Matuszewski; Hyunjin Shim; Matthieu Foll; Daniel N A Bolon; Konstantin B Zeldovich; Timothy F Kowalik; Robert W Finberg; Jennifer P Wang; Jeffrey D Jensen
Journal:  Evolution       Date:  2016-09-13       Impact factor: 3.694

7.  Discovering drugs to treat coronavirus disease 2019 (COVID-19).

Authors:  Liying Dong; Shasha Hu; Jianjun Gao
Journal:  Drug Discov Ther       Date:  2020

8.  Two sides of the same coin: A population genetics perspective on lethal mutagenesis and mutational meltdown.

Authors:  Sebastian Matuszewski; Louise Ormond; Claudia Bank; Jeffrey D Jensen
Journal:  Virus Evol       Date:  2017-03-02

9.  Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics.

Authors:  Everett Clinton Smith; Hervé Blanc; Matthew C Surdel; Marco Vignuzzi; Mark R Denison
Journal:  PLoS Pathog       Date:  2013-08-15       Impact factor: 6.823

10.  The Combined Effect of Oseltamivir and Favipiravir on Influenza A Virus Evolution.

Authors:  Louise Ormond; Ping Liu; Sebastian Matuszewski; Nicholas Renzette; Claudia Bank; Konstantin Zeldovich; Daniel N Bolon; Timothy F Kowalik; Robert W Finberg; Jeffrey D Jensen; Jennifer P Wang
Journal:  Genome Biol Evol       Date:  2017-07-01       Impact factor: 3.416

View more
  9 in total

1.  The extinction time under mutational meltdown driven by high mutation rates.

Authors:  Lucy Lansch-Justen; Davide Cusseddu; Mark A Schmitz; Claudia Bank
Journal:  Ecol Evol       Date:  2022-07-06       Impact factor: 3.167

2.  Molecular evolutionary characteristics of SARS-CoV-2 emerging in the United States.

Authors:  Shihang Wang; Xuanyu Xu; Cai Wei; Sicong Li; Jingying Zhao; Yin Zheng; Xiaoyu Liu; Xiaomin Zeng; Wenliang Yuan; Sihua Peng
Journal:  J Med Virol       Date:  2021-09-20       Impact factor: 20.693

3.  SARS-CoV-19 Mutations: is a Blessing or a Curse for Human Being?

Authors:  Zohreh Jadali
Journal:  Ethiop J Health Sci       Date:  2022-03

4.  Comprehensive analysis of genomic diversity of SARS-CoV-2 in different geographic regions of India: an endeavour to classify Indian SARS-CoV-2 strains on the basis of co-existing mutations.

Authors:  Rakesh Sarkar; Suvrotoa Mitra; Pritam Chandra; Priyanka Saha; Anindita Banerjee; Shanta Dutta; Mamta Chawla-Sarkar
Journal:  Arch Virol       Date:  2021-01-19       Impact factor: 2.574

5.  Inferring the distribution of fitness effects in patient-sampled and experimental virus populations: two case studies.

Authors:  Ana Y Morales-Arce; Parul Johri; Jeffrey D Jensen
Journal:  Heredity (Edinb)       Date:  2022-01-05       Impact factor: 3.821

6.  US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19.

Authors:  Robert W Finberg; Madiha Ashraf; Boris Julg; Folusakin Ayoade; Jai G Marathe; Nicolas C Issa; Jennifer P Wang; Siraya Jaijakul; Lindsey R Baden; Carol Epstein
Journal:  Open Forum Infect Dis       Date:  2021-12-07       Impact factor: 3.835

7.  Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution.

Authors:  Massimo Amicone; Vítor Borges; Maria João Alves; Joana Isidro; Líbia Zé-Zé; Sílvia Duarte; Luís Vieira; Raquel Guiomar; João Paulo Gomes; Isabel Gordo
Journal:  Evol Med Public Health       Date:  2022-03-29

8.  The impact of frequently neglected model violations on bacterial recombination rate estimation: a case study in Mycobacterium canettii and Mycobacterium tuberculosis.

Authors:  Susanna Sabin; Ana Y Morales-Arce; Susanne P Pfeifer; Jeffrey D Jensen
Journal:  G3 (Bethesda)       Date:  2022-05-06       Impact factor: 3.542

Review 9.  Imposed mutational meltdown as an antiviral strategy.

Authors:  Jeffrey D Jensen; Ryan A Stikeleather; Timothy F Kowalik; Michael Lynch
Journal:  Evolution       Date:  2020-10-27       Impact factor: 3.694

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.